Pharmafile Logo
Pharmafocus logo
Advanced Search

Medical Communications

Showing 15 posts of 6402 posts found.

Global study calls for overhaul of hepatitis B care to meet WHO targets

August 21, 2025 Medical Communications, Medical/ Scientific Writing Hepatology, World Health Organisation, hepatitis B, liver damage, medical study

A major global study has warned that current models of hepatitis B care are failing patients and could jeopardise the …
News

Five Facts about epilepsy

August 21, 2025 Medical Communications Five Facts, Neurology, epilepsy, neurological condition, seizures

1 Epilepsy occurs when the normal electrical activity in the brain changes. For many, the cause is unclear, but genes …
Feature
brain_anatomy_medical_head_skull_digital_3_d_x_ray_xray_psychedelic_3720x2631

FDA decision on Neurizon’s ALS therapy delayed until October

August 18, 2025 Medical Communications Coya Therapeutics, Neurizon, Neurology, US Food and Drug Administration, amyotrophic lateral sclerosis

Neurizon Therapeutics has announced that the US Food and Drug Administration (FDA) will delay its decision on the company’s Clinical …
News

FDA approves first new fibromyalgia therapy in over 15 years

August 18, 2025 Medical Communications, Research and Development Pain, Tonix Pharmaceutical, US Food and Drug Administration, chronic pain, clinical trial, fibromyalgia

The US Food and Drug Administration (FDA) has approved Tonix Pharmaceutical’s Tonmya (cyclobenzaprine hydrochloric acid) for the treatment of fibromyalgia …
News
Astra Zeneca Logo

NICE recommends Benralizumab for Rare Form of Vasculitis

August 15, 2025 Medical Communications, Research and Development AstraZeneca, Immunology, National Institute for Health and Care Excellence, vasculitis

The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as an add-on treatment for adult …
News

Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition

August 14, 2025 Medical Communications, Research and Development European Alliance of Associations for Rheumatology, European Medicines Agency, IgG4-related disease, Rheumatology, Sanofi

The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) inhibitor, rilzabrutinib, for the treatment …
News
eye1

Eyestem secures $10m to advance cell therapy for advanced eye disease

August 13, 2025 Medical Communications, Research and Development Eyestem, Opthalmology, cell therapy, dry age-related macular degeneration, geographic atrophy

Indian cell therapy company, Eyestem Research, has raised $10m in a funding round to support development of its investigational retinal …
News
bonecells

OS Therapies advances regulatory pathway for bone cancer therapy

August 11, 2025 Medical Communications, Research and Development European Medicines Agency’, Medicines and Healthcare products Regulatory Agency, OS Therapies, Oncology, Orthopaedics, US Food and Drug Administration’, bone cancer, osteosarcoma

OS Therapies has announced significant progress in its regulatory strategy for OST-HER2, its lead immunotherapy candidate for preventing or delaying …
News
640px-eye_iris

NICE recommends treatment for rare genetic eye disorder

August 11, 2025 Medical Communications Chiesi, Leber Hereditary Optic Neuropathy, NHS England, National Institute for Health and Care Excellence, Opthalmology, Rare Diseases

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending Cheisi’s idebenone (Raxone) within its …
News

ARTBIO expands board and establishes technical advisory board

August 11, 2025 Medical Communications, Research and Development ARTBIO, Corporate, Oncology, advisory board, radiopharmaceuticals

ARTBIO, a radiopharma company developing radioligand therapies (RLTs), has appointed four new members to its board of directors and formed …
Appointment
pills-384846_960_720

Lilly reports positive results from trial of obesity candidate

August 8, 2025 Medical Communications, Research and Development Eli Lilly and Company, Obesity, cardiovascular risk, high blood pressure, obesity

Eli Lilly and Company (Lilly) has announced topline results from its phase 3 ATTAIN-1 trial, showing that orforglipron – a …
News
az_vaccine

Rollout of world-first gonorrhoea vaccine programme begins under NHS

August 8, 2025 Medical Communications 10 Year Health Plan, Genito-Urinary system, Infections and infestations, NHS, gonorrhoea, sexual health, sexually transmitted infections, vaccination

From 4 August, sexual health clinics in England have been able to offer a free vaccine – the 4CMenB vaccine …
News
drug-trials

Faron reports increased remission rate in trial for myelodysplastic syndrome candidate

August 7, 2025 Medical Communications, Research and Development Faron Pharmaceuticals, Oncology, US Food and Drug Administration, acute myeloid leukemia, myelodysplastic syndrome

Faron Pharmaceuticals has reported a rise in complete remission (CR) rates among patients with frontline high-risk myelodysplastic syndrome (HR-MDS) in …
News

PLL Therapeutics to present ALS research strategy at Bioshares Biotech Summit

August 7, 2025 Medical Communications, Research and Development Bioshares Biotech Summit, Neurology, PLL Therapeutics, amyotrophic lateral sclerosis, neurodegenerative diseases

French biotech, PLL Therapeutics, will present its approach to early detection and treatment of Amyotrophic Lateral Sclerosis (ALS) at the …
News
brain-770044_960_720

Lilly’s drug for early Alzheimer’s shows promising results

August 6, 2025 Medical Communications, Research and Development Alzheimer's, Eli Lilly, Neurology, dementia

Eli Lilly (Lilly) has announced positive new data from the long-term extension of its phase 3 study, showing that Kisunla …
News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025